Nuvectra is a neurostimulation medical device company focused on the development and commercialization of its neurostimulation technology platform for the treatment of various disorders through stimulation of tissues associated with the nervous system. Co.'s neurostimulation technology platform has the potential to provide treatment to patients in several neurostimulation markets, including spinal cord stimulation (SCS), sacral neuromodulation, deep brain stimulation, and other emerging neurostimulation markets. Co.'s Algovita® SCS system (Algovita), is an application of its neurostimulation technology platform and is indicated for the treatment of chronic pain of the trunk and/or limbs. The NVTR stock yearly return is shown above.
The yearly return on the NVTR stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2019 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the NVTR annual return calculation with any dividends reinvested as applicable (on ex-dates).
|